Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
35 /100
MEDIUM RISK
Score updated Oct 13, 2026

FATE — Fate Therapeutics, Inc. Dilution Risk Tracker

Track FATE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track FATE — Get alerts when the score changes →

As of October 13, 2026, Fate Therapeutics, Inc. (FATE) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. Fate Therapeutics, Inc. has a market capitalization of $255.22M, 119.82M shares outstanding, 155 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
40
📊 Float Risk
7
⚠️ Warrant Exposure
40
🔄 Convertible Debt
35

Dilution Forecast

⛅
Watch
Minor dilution signals detected
model est. 19%
🔄 Reverse Split model est. 30%
• 50-day avg $1.61 approaching $1 threshold
🔁 Convertible Conversion model 15%
• Convertible debt present: 7.8% potential dilution
🔔 Track FATE — Get forecast alerts →

Market Data

Market Cap$255.22M
Shares Outstanding119.82M
Float101.89M
Cash$153.77M
Debt$23.40M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore35/100DilutionWatch score record
Shares Outstanding119.82MVerified float table or market cache
Public Float101.89MVerified float table or market cache
Market Cap$255.22MMarket data cache
Cash Runway15.2 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 29.4% shares (2026Q1 vs prior)
155 institutional holders · 93.98M shares
#1 Redmile Group, LLC 12.87M shares
#2 JOHNSON & JOHNSON 10.14M shares
#3 BlackRock, Inc. 10.07M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest10.76M
Days to Cover5.3
% of Float10.6%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2016-03-03
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual FATE Dilution Snapshot

Fate Therapeutics, Inc. (FATE) has a DilutionScore of 35/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

FATE's DilutionScore is currently 35/100 (Medium risk), with 3 score changes tracked over 89 days. The score improved from 34/100 (Medium risk).

Period Score Risk Level Duration
Oct 13, 202635/100MEDIUM1 day
Aug 14 – Oct 12, 202634/100MEDIUM59 days
Jul 17 – Aug 13, 202630/100MEDIUM28 days
Jul 16, 202631/100MEDIUM1 day

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

FATE shares outstanding have increased 1.0% from 115.35M (Mar 2026) to 116.56M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 25, 2026116.56M101.89M▼ 0.05%
May 24, 2026116.56M101.93M▼ 0.52%
May 17, 2026116.56M102.46M▲ 0.03%
May 15, 2026116.56M102.43M▲ 0.25%
May 10, 2026116.28M102.17M▲ 0.54%
Mar 05, 2026115.35M101.62M▲ 0.11%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track FATE Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment FATE files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking FATE — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for FATE
FATE FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.